Product Name	Business Class Bespoke Injury & Travel Insurance
Insurer	CHUBB European Group SE
Responsible For	No
Manufacture	
Advised Sales	No
Product Type	Accident & Health
Availability	Manually underwritten / prior submit to insurers / e-traded with insurers
Target Market	Companies from micro/SME through to large corporates wishing to purchase group personal accident &/or business travel insurance in respect of their
	employees.
Non-Target	Non-Commercial customers / individual customers.
Market	
(Unsuitable	
Markets)	
Why Is This	Specifically designed wording offering a range of Personal Accident covers: death,
Product Suitable	a range of specified permanent disabilities, broken bones, hospital cash all due to
	accidental bodily injury
Are There Any	Yes – Business Travel along with other sub-sections within PA cover.
Optional Covers	
Distribution	SSR wholesale this product through other insurance intermediaries on behalf of
Methods	CHUBB. This product can be obtained by SSR on a manual referral basis or through
	the CHUBB Ignite underwriting system, but ultimate underwriting of the product is
	CHUBB.
Is This Product	Yes, this product is deemed to be providing fair value as it is specifically targeted in
Providing Fair	terms of coverage and function and is distributed via insurance intermediaries who
Value	understand the requirements of their clients.
Risk To Fair Value	Duplication of covers elsewhere or failure to purchase required optional elements.
Mitigation	Excessive commission or fees may undermine the value of the product as well.
	Care to be taken by distributors to ensure covers offered are not duplicating by
	other offerings. Commission levels charged by SSR and provided to distributors are
	within market norms and monitored for fairness regularly.
Other Information	Product documents can be provided upon request which clarifies position of
To Consider	product on standard exclusions and limitations to product coverage.
	Product manufacturer/insurer will produce their own Fair Value Statement and
	Target Market Statement.

Published	September 2023
Planned review	September 2024